pharmaceuticals Review Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters Teresa Iannaccone 1, Carmine Sellitto 1,2,* , Valentina Manzo 1,2 , Francesca Colucci 1, Valentina Giudice 1 , Berenice Stefanelli 1 , Antonio Iuliano 1, Giulio Corrivetti 3 and Amelia Filippelli 1,2 1 Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, 84081 Baronissi, Italy;
[email protected] (T.I.);
[email protected] (V.M.);
[email protected] (F.C.);
[email protected] (V.G.);
[email protected] (B.S.);
[email protected] (A.I.); afi
[email protected] (A.F.) 2 Clinical Pharmacology and Pharmacogenetics Unit, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, 84131 Salerno, Italy 3 European Biomedical Research Institute of Salerno (EBRIS), 84125 Salerno, Italy;
[email protected] * Correspondence:
[email protected]; Tel.: +39-089673848 Abstract: Pharmacogenomics can identify polymorphisms in genes involved in drug pharma- cokinetics and pharmacodynamics determining differences in efficacy and safety and causing inter-individual variability in drug response. Therefore, pharmacogenomics can help clinicians in optimizing therapy based on patient’s genotype, also in psychiatric and neurological settings. Citation: Iannaccone, T.; Sellitto, C.; However, pharmacogenetic screenings for psychotropic drugs are not routinely employed in diagno- Manzo, V.; Colucci, F.; Giudice, V.; Stefanelli, B.; Iuliano, A.; Corrivetti, sis and monitoring of patients treated with mood stabilizers, such as carbamazepine and valproate, G.; Filippelli, A. Pharmacogenetics of because their benefit in clinical practice is still controversial. In this review, we summarize the current Carbamazepine and Valproate: Focus knowledge on pharmacogenetic biomarkers of these anticonvulsant drugs.